Description

Ipamorelin Research Topics:

1. 1. Selective GH Release:

      Ipamorelin can release GH with similar potency to GHRP‑6 in both rat pituitary and swine models. [1]

   2. Bone Growth Development:

      Chronic administration in adult rats increased tibial growth rate and body weight without altering IGF‑I or bone remodeling markers. [2]

   3. Supports Gastrointestinal Motility:

      In rodent models of postoperative ileus, Ipamorelin dose-dependently sped up return of bowel function, increasing fecal output, food intake, and body weight. [3]

   4. Counters Glucocorticoid-Induced Bone Loss:

      In adult rats treated with glucocorticoids (which normally decrease bone formation), co-administration of Ipamorelin prevented this bone loss, suggesting protective effects in catabolic conditions. [4]

Reference Citation:

1. Raun, K., Hansen, B.S., Johansen, N.L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(6), 552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/

2. Burgos, R.A., Meier, E., Reynolds, N., et al. (1999). Ipamorelin, a novel growth hormone releasing peptide, induces longitudinal bone growth in rats. European Journal of Endocrinology, 141(2), 180–183.
   https://pubmed.ncbi.nlm.nih.gov/10373343/

3. Bjurling, M., et al. (2011). The growth hormone secretagogue ipamorelin improves gastrointestinal transit in a postoperative ileus model in rats. European Journal of Pharmacology, 657(1–3), 168–175.
   https://pubmed.ncbi.nlm.nih.gov/21320445/
4. Andersen, J.L., et al. (2001). Growth hormone secretagogues stimulate longitudinal bone growth in rats and prevent bone loss induced by glucocorticoid treatment. Journal of Bone and Mineral Research, 16(11), 2103–2110. https://pubmed.ncbi.nlm.nih.gov/11697804/